Answers are grounded in this paper and cite their sources.
There is a severe discrepancy between the number of liver transplant candidates and number of donor livers available for transplantation in the United States at the present time. Nothing illustrates this better than the rapid rise in the number of patients currently on the United Network for Organ Sharing (UNOS) waiting list for liver transplantation (1). This relative shortage of donor organs has fueled the recent controversy over the distribution and allocation of donor organs. One of the principal issues in this controversy is the marked difference in the number of days on the transplant waiting list before receiving a liver transplant in different parts of the country. There are many possible explanations for these regional differences. The explanations include the possibility that the present system of donor organ identification, retrieval, distribution and allocation results in unequal distribution of livers throughout the country. This is a contentious area, about which many interested parties, both inside and outside the transplant community, hold conflicting views. In addition, there is the possibility that patients in different parts of the country are placed on the waiting list at different points in the natural history of their diseases. This practice could result in a patient getting priority for liver transplantation based on nothing more than an accident of geography. Furthermore, there is the concern that, because of long waiting times in certain regions, there is a pressure on transplant programs to list patients early, before they actually require transplantation, a practice referred to as 'waiting list inflation.' In order to address these concerns, United Network for Organ Sharing (UNOS) recently asked the various organ specific committees to develop organ specific criteria for entry into the national waiting list. On February 21, 1997, the liver transplant community met at the Natcher Center on the campus of the National Institutes of Health (NIH) to formulate minimal listing criteria. The meeting was cosponsored by the American Society of Transplant Physicians (ASTP) and the American Association for the Study of Liver Diseases (AASLD). It also was endorsed by the Liver and Intestinal Committee of UNOS. A subcommittee of the UNOS Liver and Intestinal Committee had already developed liver-specific minimal listing criteria. These were used as a starting point for discussion and changes were recommended where the UNOS criteria were felt to be too restrictive, not restrictive enough or in need of modification. While we, as organizers of this meeting, recognize that the access of particular patients to an allograft is influenced by rules governing the allocation and distribution of donor organs, the objectives of this conference were confined to the development of minimal listing criteria for potential liver transplant recipients. The present paper summarizes the views of the participants regarding minimal listing criteria for orthotopic liver transplantation for adult patients. A companion paper discusses minimal criteria for pediatric candidates (2). WHAT IS MEANT BY 'MINIMAL CRITERIA' Before considering the significance of minimal criteria, it is necessary to define the purpose of the liver transplant waiting list. It was agreed by the participants of the conference that when a program places a patient on the waiting list, it should signify that the program would be prepared to transplant that patient immediately, should a donor liver become available. Patients should not be placed on the waiting list simply because it is perceived that he or she will likely need liver transplantation a some point in the future. It was agreed that the minimal listing criteria should be simple, practicable, based on existing published or, in some cases, unpublished clinical research, and have received broad agreement among the liver transplant community. The simplicity of the criteria would be enhanced by avoiding subjective qualifiers such as 'refractory', 'intractable', 'severe', etc. The criteria should be readily verifiable, and the verification process should become a mechanism for UNOS and the regional review boards (see below) to collect ongoing data. It was also agreed that the minimal listing criteria should be regularly reviewed by the transplant community, and modified where appropriate. This provision is necessary to accommodate the rapid developments in liver transplantation medicine and surgery, whereby previous contraindications cease to be impediments to successful transplantation. A frequently expressed fear of the participants of the conference was that by writing a set of specific minimal criteria which reflect current practice, we might be constructing a set of immutable rules which, in later years, would restrict access to transplantation of patients with transplantable disorders. Finally, it must be emphasized that it is not mandatory for all patients meeting the minimal listing criteria to be listed for transplantation or be transplanted. The final decision whether to list a patient ultimately depends on the clinical judgment of the patient's physicians and the local transplant program's selection committee. MONITORING THE LISTING PROCESS A key component of the development of listing criteria is the establishment of regional review boards. The composition of the review boards has yet to be determined by UNOS, but would comprise physicians drawn from liver transplant programs within that area. The purpose of the regional boards will be 3-fold: To monitor adherence to the minimal listing criteria. To arbitrate in difficult or exceptional cases, that fall outside the standard minimal listing criteria. To facilitate UNOS to gather data on the conduct of, and consequences of, the minimal listing criteria in practice. It is presumed that there will be regional variation in the extent of review conducted by the regional review boards. However, it is anticipated that a standard report form will allow collection of standardized data on all patients entering the listing process, including the cases, presumably the majority, who clearly meet the minimal criteria outlined above, and who do not need to be reviewed in detail. NON-DISEASE-SPECIFIC CRITERIA It was agreed by the participants that, in general, a minimum criterion for a patient with chronic liver disease to qualify for the waiting list for liver transplantation should be a 90% or less chance of surviving one year. It is also imperative that a mechanism to enter the waiting list exist for exceptional patients, whose predicted one year survival exceeds 90%, but who have other compelling indications for liver transplantation. An example would be a patient with well-compensated Primary Biliary Cirrhosis, who has severely impaired quality of life as a result of pruritus. It is believed that presentation of such patients to the regional review boards is the best way to provide access to the waiting list for exceptional cases, and that consideration of these cases will be one of the important functions of the review boards. However, for several of the busiest UNOS regions, reviewing all listings would be impracticable. Thus, it was believed that criteria developed needed to be straightforward and simple to allow easy verification by the transplant program and by UNOS. The survival of patients with cirrhosis is dependent on Child-Pugh score (Table 1) (3). This observation is supported by a 15-year study of 620 patients with chronic liver disease from Innsbruck University (4). The estimated 1-year and 5-year survivals were 95% and 75% for patients with Child-Pugh class C, respectively. Based on this institutional review and other studies of natural history, it is apparent that the survival of patients with cirrhosis is significantly decreased after the development of decompensation, usually defined as the onset of any of the following: ascites, jaundice, variceal hemorrhage, or encephalopathy. For example, in a 7-year study of the natural history of chronic hepatitis C with cirrhosis, the probability of decompensation after the diagnosis of cirrhosis was relatively low: 12% at 3 years, 18% at 5 years and 29% at 10 years (5). However, survival was significantly different after decompensation: 91% of cirrhotic patients who remained without decompensation were alive 5 years later, whereas only 50% were alive 5 years following an episode of decompensation. Once decompensation occurred, approximately 20% of patients died within one year. Ascites and variceal bleeding were the most common manifestations of decompensation. Similar natural history data, in a cohort of patients with cirrhosis due to many causes, were reported by the Barcelona group (6). Decompensation occurred in 58% of patients in the first 10 years of observation. Ascites was the most common decompensating event, followed by jaundice, hepatic encephalopathy, and variceal bleeding. The median survival in the cirrhotic who remained stable without decompensation was 8.9 years, whereas the median survival from the first presentation of decompensation was 1.6 years.Table 1: Child-Turcotte-Pugh ScoreaAscites confers a poor prognosis, in part, because of the associated development of spontaneous bacterial peritonitis, and hepatorenal syndrome, both of which further shorten survival. In another report from the University of Barcelona, 25% of cirrhotic patients who developed ascites, experienced an episode of spontaneous bacterial peritonitis within the following year (7). The 1-year cumulative probability of survival was 66% in the cirrhotics with ascites but without an episode of spontaneous bacterial peritonitis, compared to 38% in those with an episode of spontaneous bacterial peritonitis. Hepatorenal syndrome is an even more ominous complication of ascites. The probability of hepatorenal syndrome after the onset of ascites was 18% at 1 year, and 39% at 3 years in the Barcelona series. The median survival after the onset of hepatorenal syndrome was only 1.7 weeks (8). Regarding the influence of variceal bleeding on the natural history of cirrhosis, the Barcelona studies indicated that just under 40% of cirrhotics without previous decompensation experienced bleeding due to portal hypertension over a 10 year period (7). The survival after an episode of variceal hemorrhage may be confounded by therapeutic interventions. Combining data from disparate series, it appears that mortality after variceal hemorrhage is high despite treatment with either sclerotherapy, shunt surgery, or transjugular portosystemic shunts (TIPS). For example, in a study comparing sclerotherapy and distal splenoral shunt surgery in the prevention of recurrent variceal bleeding, the 1-year survivals were 92% versus 75%, and 4-year survivals were 75% and 43% respectively (9). In a different study of TIPS for management of recurrent bleeding, the overall 1-year survival was 87%, with rates 100%, 86%, and 73% among patients with Child-Pugh classes A, B, and C respectively (10). In summary, after reviewing published data, it is clear that patient with cirrhosis and a Child-Pugh score of 7 or greater, which places the patient in Class B or C, would meet the requirement for a predicted 1-year survival of 90% or less. In addition, patients who experience gastrointestinal bleeding caused by portal hypertension, or a single episode of spontaneous bacterial peritonitis (SBP), irrespective of their Child-Pugh score, would meet this minimal criterion. By contrast, a patient with well compensated-cirrhosis, i.e., Child-Pugh class A, without a history of portal hypertensive bleeding or SBP, would not meet these minimal criteria, and would require approval of the regional review board in order to gain access to the waiting list on exceptional grounds. DISEASE-SPECIFIC CRITERIA Much of the day's discussion related to whether unique criteria should be developed for the various causes of liver disease. In order to accomplish this, the parenchymal liver diseases were divided into specific categories including chronic hepatitis B, chronic hepatitis C, autoimmune hepatitis, alcoholic liver disease (ALD), cholestatic liver disease: primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and secondary biliary cirrhosis, and finally metabolic liver diseases (hematochromatosis, Wilson's disease and alpha1 anti-trypsin deficiency) and each disease was addressed individually. It was a general consensus that for all causes of cirrhosis, a Child-Pugh score of 7 or more, i.e. Class B or C, or the presence of portal hypertensive gastrointestinal bleeding should allow entry onto the waiting list. For cirrhosis caused by chronic hepatitis B or C, or autoimmune liver disease, these general minimal listing criteria were adequate without the addition of any diagnosis-specific criteria. Many speakers emphasized that the first requirement was for appropriate medical or surgical management, even in patients who met the minimal standards for entry onto the waiting list. An example is autoimmune liver disease, which is very steroid responsive, even when showing features of decompensated cirrhosis (11). The minimal listing criteria merely allow access to the waiting list, without requiring prior review by the regional review board. It remains in the domain of the individual transplant center to determine whether to place an individual patient with decompensated autoimmune disease on the list, or to initiate medical management, or to do both. Fulminant Hepatic Failure The sole minimal listing criterion for patients with fulminant hepatic failure (FHF), regardless of etiology, is the onset of Stage 2 hepatic encephalopathy in a patient who meets the standard definition of FHF, shown in Table 2. It important to emphasize that many of the patients who meet this criterion will recover without transplantation (11). Therefore, continuous monitoring for recovery of liver function is required in these patients.Table 2: Definitions of Fulminant Hepatic FailurePatients with subacute hepatic failure (see Table 2 for definition), also have a high mortality, and should be eligable for placement on the list, without prior approval of the regional review committee. Alcoholic Liver Disease It was agreed that the general minimal listing criteria described above for patients with chronic parenchymal liver disease should apply to patients with alcoholic liver disease also. It is the possibility of returning to alcohol abuse that separates patients with alcoholic liver disease from those with other forms of chronic liver disease. The discussion at the February meeting drew on the results of a recent NIH-sponsored conference entitled 'Liver Transplantation for Alcoholic Liver Disease,' at which data were presented showing a broad consensus among transplant professionals that a history of abstinence from alcohol is an important criterion in selection of alcoholic patients for liver transplantation. Eighty five per cent of the liver transplant programs in the United States and Europe stated that they either require a fixed period of abstinence, most commonly lasting 6 months, or at least place a value on established abstinence, when assessing which alcoholic patients should be approved for liver transplantation (13). The impact of the requirement for 6 months abstinence on rates of alcohol is However, one of the of UNOS is that be based on consensus there is a consensus for requiring that most alcoholic patients should be from alcohol for at least 6 months before they be listed for liver transplantation. The 6 abstinence a number of it for recovery from the of recent alcohol Decompensation in patients with chronic alcoholic liver disease is the result of alcoholic hepatitis on established liver these patients abstinence from many will to the point that liver transplantation may not be needed The 6 abstinence in patients with alcoholic hepatitis from consideration for liver transplantation, a group of patients who were from transplantation in the criteria developed by the UNOS Liver and Intestinal it is that the data regarding the of the 6 abstinence period as a of are conflicting However, it should be emphasized that 6 months abstinence from alcohol is not an adequate minimal standard by for placement on the liver transplant waiting list. There is agreement that alcoholic patients must be by a abuse and must with the of the abuse (13). that the minimal criteria for listing an alcoholic patient with liver disease should be all of the following: by the center Child-Pugh point score of 7 or greater, or portal hypertensive bleeding, or an episode of spontaneous bacterial peritonitis, by a abuse and reported abstinence of at least 6 months at of patients with alcoholic liver disease, who have not for 6 months and yet the transplant program are candidates for liver transplantation, be referred to the regional review boards for It also that the criteria regarding abstinence from and by a abuse also apply to those patients with which include alcoholic liver disease, alcoholic liver disease and chronic hepatitis C There was discussion regarding the of a or agreement to at the of by the transplant many programs include such in their it was agreed that the to such should and not become a UNOS Finally, the conference participants the appropriate to the alcoholic patient who alcohol in the process, or on the transplant waiting list. The consensus was that such patients should be from the list. These patients could the process after at the of the transplant center and as by the abuse The rules regarding abstinence from alcohol and approval by the transplant center and abuse before placement on the waiting list, cases may be to the regional review committee. The cholestatic liver primary biliary cirrhosis and primary sclerosing cholangitis the 2 diseases for which the natural history of the disease is best The Liver and Intestinal Committee of UNOS recommended the which were developed as for and These 2 are shown in the also recommended the minimum listing criterion would be a score which a 95% chance of surviving the year. However, the participants at the conference believed that the 95% standard was too that the standard minimum criterion for patients with parenchymal liver disease was a than of in one year. Primary Biliary The of five from which a was The were the patient's and and of However, the score as a sole criterion of for the waiting list has some For example, is one of the 5 used to the it may to an of the patient's for liver For example, a year patient with liver function would meet the criteria by the UNOS Liver and Intestinal as a criterion for which is currently the treatment of for patients with has a on survival yet has a more on the because the is in the Thus, the in patients may their the to mortality in patients with such as variceal bleeding. the score is not easy to without the of (see Finally, the of the disease it more difficult to for individual patients that the only the of a disparate are to have these available on the UNOS to facilitate their into Primary The for and presence of cirrhosis on liver to of This several of the listed above for the disease but some as The first is the of of this in a of the a liver in a patient where the would not be the in over even be related to of cholangitis or biliary Finally, the system is difficult to requiring In the of the minimal listing criteria simple and we the following standard listing criteria for patients with or Child-Pugh score of 7 or the for cholestatic liver diseases as shown in Table 1) or the development of portal hypertensive gastrointestinal bleeding. In addition, or patients with a that than 1-year mortality meet minimal criteria for listing for liver transplantation. many patients with do not have a recent liver we that the presence of and could be used as for the of cirrhosis and be a score of 2 for when the Patients with of or recurrent but who do not meet the criteria listed above, should be referred to the regional review board. For all other forms of chronic liver disease to cirrhosis Wilson's disease, 1 anti-trypsin cirrhosis, secondary biliary cirrhosis and the standard specific minimal listing criteria would There were some unique listing criteria For syndrome, we that a portal is the treatment of in the patient who not yet have cirrhosis Liver transplantation is appropriate in patients with portal has or is not In patients with established cirrhosis, In patients who have a fulminant Patients with Wilson's disease be listed as they meet appropriate criteria. of these patients would meet the standard listing criteria, it was not believed that unique criteria need be have reported a score, based on and which patients to of without transplantation on the of liver transplantation in patients were not on of more recent studies an survival in patients with confined to the liver There was agreement at the February conference that the minimal listing criteria for patients with primary liver should any patient with confined to the irrespective of or number of after had to to the portal or organs. The under consideration for liver transplantation or and finally Before considering whether a particular patient with disease meets minimal listing criteria, primary of the should be Patients with outside of the i.e. portal or local should not be listed for liver transplantation. Patients with should be reviewed by the regional review board. It was that severe on the entry of hepatic patients to the waiting list could development of hepatic transplantation, for hepatic It was agreed that that include liver transplantation, to hepatic should be reviewed and approved by the regional review boards. Liver transplantation may be appropriate in in which the of is even in the of an For example, it was agreed that listing for transplantation was appropriate for patients with cirrhosis associated with chronic hepatitis B or C, by an of or an of with the on 3 in the of a It is to in a one conference minimal listing criteria, which to the requirement for simplicity and of for for liver transplantation. There are a number of for which liver transplantation is indicated patients will meet the minimal listing criteria stated include liver disease, and These diseases or that it would not be for the regional review boards to with on a by than to criteria for each of the diseases. The apply to organ that include liver transplantation. THE It was the consensus of the that there should be contraindications to placement of patients on the liver transplant waiting list. It is to relative which require to the regional review in order to gain access to the waiting list. These relative contraindications are in some cases the of the indications cirrhosis, without a history of such as variceal hemorrhage or in the previous 6 months by a patient with a diagnosis of alcohol abuse or in the previous 6 months by a patient with a diagnosis of abuse hepatic other than relative contraindications are of current medical practice, and may become in the has the in treatment of that this may the way of previous on transplantation of patients with which are It was the consensus of the that UNOS should not formulate criteria to patients from the liver transplant waiting list. This was a clinical decision best to the transplant
No takes yet. Share an insight, caveat, or question.
Lucey et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: